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One hundred and seventy-seven former heroin addicts, consisting of 85 who were newly admitted to a
methadone maintenance program and 92 who had received methadone for a mean period of30 months, were
prospectively studied for up to 2 years in order to determine: (1) the effect of heroin withdrawal on the
hepatic abnormalities, and (2) the incidence of HBsAg, anti-HBs, and anti-HCc as indices ofthe frequency
of hepatitis B virus infection. Our study indicates that (1) hepatic abnormalities persist when heroin is
discontinued and are not temporally related to drug and/or needle usage, and (2) that 71% of subjects had
either HBsAg or anti-HBs; anti-HBc was tested for in 16 patients and was present in 100o, although 9 ofthe
16 were both HBsAg- and anti-HBs-negative. This study suggests that hepatitis B is largely responsible for
the liver dysfunction. It is proposed that an abnormality in immune function, induced by heroin, is
responsible for the high incidence of chronic hepatitis. Attention is drawn to the similarity between former
drug addicts and hemophiliacs, since both develop chronic hepatitis in spite of anti-HBs in the serum.
INTRODUCTION
Abnormal liver function tests have been found in up to 83% ofasymptomatic drug
addicts entering a detoxification program [1,2]. The cause ofthese abnormalities has
not been determined, although a direct toxic effect of the drug [3], contamination of
the drug with othertoxic agents[4], concomitant use ofalcohol[1] and viral hepatitis
[5,6] have all been suggested etiologies. Although most studies[2,7] have shown a low
incidence of HBs-antigenemia in these patients, recent studies employing sensitive
assays for both HBsAg and anti-HBs [2,8] have shown a high incidence of prior
infection with hepatitis B virus (HBV).
In view of the uncertainty regarding the etiology of hepatitis in drug users, the
present study was designed to assess: (1) the effect of heroin withdrawal on the
hepatic abnormalities, since their persistence would exclude a lesion temporally
related to injection ofthe drug and/or contaminants, and (2) the prevalence ofHBV
infection as determined by the incidence of HBsAg, anti-HBs, and anti-HBc.
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Patients
Two groups of patients were studied. Eighty-five patients were newly admitted to a
methadone program and had not received methadone prior to the study (Group A).
Ninety-two patients (Group B) had received methadone for periods of 2 months to 6
years (mean duration of 30 months) before the study. None of the patients showed
evidence of alcoholic liver disease. Twenty percent had intakes of alcohol which
varied between 3 and 6 ounces daily. None admitted to an intake ofalcohol in excess
of 6 ounces. The dosage ofmethadone was similar in both groups(mean 35 mg/day).
The ages of the patients ranged from 21 to 59 years, mean 29 years.
Methods
Serum GOT, alkaline phosphatase, and bilirubin were measured on entry to the
study and were followed serially at intervals ofthree months in Group A patients and
six months in Group B patients. Testing for hepatitis B surface antigen was done by
radioimmunoassay (RIA) (Austria II, Abbott Laboratories, No. Chicago, IL). Initial
anti-HBs testing was done by agar gel diffusion (AGD) and counter immunoelectro-
phoresis (CEP). Subsequent testing during follow-up was done bypassive hemagglu-
tination (Electronucleonics Laboratories, Bethesda, MD). Anti-HBc testing was
done by radioimmunoassay (courtesy of Dr. V. McAuliffe) in 16 patients who were
all in Group B and who had been on heroin for a mean (± SD) period of 8.6 (± 5.3)
years, followed by methadone for a mean (- SD) period of 4.4 (±.2.2) years. These
16 patients were selected at random.
Results
On initial testing, SGOT elevations were found in 65% of newly admitted patients
and in 76% of patients already maintained on methadone. The abnormalities were
minor, and the mean value for newly admitted patients was the same as that for
patients already on therapy (Table 1). Two ofthe newly admitted patients had acute
viral hepatitis on entry to the studyand were excluded from the group analysis. There
was no significant difference between serum alkaline phosphatase and bilirubin levels
for the two groups of patients (Table 1).
TABLE I
Liver Function Tests on Entry to Study
Newly admitted On therapy Normal
Number of patients 85 92
Male:Female 61:24 78:14 -
SGOT abnormalities
Number of elevated levels 55(65%o) 70(76%)
Mean level (± SEM) 64 * 9 64 * 6 15-35 units
Bilirubin abnormalities
Number with elevated levels 1 0
Mean level (t SEM) 0.41 * .07 0.34 ± .02 <1.50 mg/ 100 mm
Alkaline phosphatase abnormalities
Number with elevated levels 1 7
Mean level (t SEM) 47 i 2 55 ± 3 10-70 IU
HBsAg-positive in serum 6 3 -
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Serial evaluation of SGOT levels in newly admitted patients showed no significant
change in mean levels after patients had been on methadone for up to 2 years. Serial
follow-up of long-term methadone maintenance patients similarly showed no signifi-
cant change in SGOT levels. Seventy-three percent of patients with initially normal
SGOT levels in Group A had elevations on subsequent testing, as did 64% ofpatients
from Group B. Thus, 67% of patients with normal SGOT levels initially had
elevations during subsequent testing.
The overall incidence of HBsAg was,6%. There was no significant difference in the
incidence of HBs-antigenemia in patients who had not taken methadone and those
already on therapy. Only one patient had demonstrable anti-HBs when testing was
done by AGD or CEP; however, when subsequent testing was done by passive
hemagglutination, 44 of 68 (65%) were found to have anti-HBs, irrespective of liver
function test abnormality or of duration of methadone therapy. Anti-HBc was done
in 16 patients of whom 9 were both HBsAg- and anti-HBs-negative; all 16 patients
had anti-HBc present. Table 2 shows the duration of heroin use and methadone
therapy in the 16 patients tested for anti-HBc.
Of the 9 patients who had no detectable anti-HBs, 7 had abnormal SGOT values
(mean 69 ± 40). Ofthe 7 patients who did have detectable anti-HBs, 5 had abnormal
SGOT values (52 ± 28). Thus, there was no significant difference in the frequency of
SGOT abnormalities in patients with and without anti-HBs. This analysis holds true
for the larger group of patients in whom anti-HBc was sought, as well.
DISCUSSION
This study confirms the previously reported high incidence ofSGOT abnormalities
in a randomly selected population of as'ymptomatic drug users. Furthermore, the
frequency with which initially normal SGOT levels became abnormal suggests that
the incidence of SGOT abnormalities may approach 100% if samples are tested with
sufficient scatter in time. The persistence of the SGOT abnormalities after 2 years of
TABLE 2
Results of Anti-HBc, Anti-HBs Testing in 16 Randomly Selected Subjects
Subject Age Sex Years on heroin Years on methadone SGOTa Anti-HBsb Anti-HBC
MB 31 F 7 4 17 8 +
FH 29 M 2 6 51 8 +
LB 30 M 10 Newly admitted 71 32 +
KR 23 F 6 3 96 128 +
LJ 28 M 12 3 38 32 +
AE 28 F 3 7 64 128 +
Ci 51 M 19 6 24 32 +
BF 29 F 6 6 32 0 +
LD 29 F 6 3 131 0 +
RB 37 M 7 1.5 48 0 +
ES 47 M 22 7 51 0 +
WW 25 M 7 1 32 0 +
JW 34 F 9 3 79 0 +
RM 35 M 4 5 74 0 +
CR 29 M 9 2 136 0 +
DE 28 F 8 8 39 0 +
aSGOT in karmen units/ml,
McAuliffe
normal 35; btiter of anti-HBs by PHA; Cradioimmunoassay, courtesy of Dr. V.
137follow-up, in some cases after 7 years of heroin abstinence, is in keeping with the
observations of others [9,10], but in contrast to the findings in one study [11],
although the authors of that study point out differences in their addict population
from that generally encountered. Chronic liver dysfunction, temporally unrelated to
heroin and/ or needle use, thus results in these patients. There is little evidence that
heroin itself induces changes in liver function, or that contaminants are important in
the pathogenesis of the liver disease [12,13]; similarly, alcohol has generally not been
a significant factor in the causation of the liver disease in these patients. Although
alcohol consumption is frequently high in drug addicts, liver histology has generally
shown the features of chronic hepatitis (compatible with unresolved viral hepatitis)
[2,14]. The most likely lesion that accounts forthe transaminase abnormalities is thus
viral hepatitis, giving rise to chronic (unresolved) hepatitis.
The incidence of HBsAg and anti-HBs was 71%, well in keeping with the
experience of others. However, when anti-HBc was sought in 16 patients, 9 ofwhom
were HBsAg- and anti-HBs-negative, it was positive in all. This information is of
major interest since it indicates that in a randomly selected group of 9 patients, 7 of
whom had abnormal SGOT levels and none of whom had detectable HBsAg or anti-
HBs, there was evidence for HBV infection in 100%. Indeed, anti-HBc has been
shown to be a more sensitive indicator of HBV infection than the other serological
markers [15] and it has been suggested that it correlates well with viral replication in
the hepatocyte. The presence of anti-HBc in these patients thus may indicate that
viral replication is occurring in the liver cells. This provides further evidence that the
HBV is responsible for the liver disease in these patients. If, indeed, the hepatic
abnormalities are related to HBV infection, the frequency of unresolved hepatitis
after this infection would be 7 to 8 times greater than the incidence in the general
population, where it is estimated at 10% [16]. Furthermore, it is unusual to lose
HBsAg and then develop chronic hepatitis; Redeker [16] studied 429 patients with
acute icteric type B hepatitis and found that all the patients who developed chronic
hepatitis remained HBsAg-positive. In no instance was the loss of HBsAg followed
by chronic hepatitis. The situation in the drug addict is clearly different and may be
similar to the situation in hemophiliacs, where chronic hepatitis has been described,
despite clearance of HBsAg and the presence in the serum ofanti-HBs [17]. It is thus
possible that former drug addicts and hemophiliacs represent a unique population, in
that they develop chronic hepatitis despite the presence of excess anti-HBs, long
considered a protective or neutralizing antibody. This may be related to the fact that
both groups are exposed to frequent transfusions, with the possible risk of constant
re-infection. Naturally, this risk is more significant in the drug addicts, but even
hemophiliacs could be exposed, since blood containing anti-HBc, in the absence of
HBsAg, has been shown to be infectious [18]. Routine blood screening would thus
not detect viral particles. The possibility of non-A, non-B hepatitis is a real one,
particularly in view ofits parenteral transmissibility and potential for causing chronic
hepatitis, but in the absence of a serological marker, this remains pure conjecture.
A second explanation for this anomaly, of persistent hepatitis in drug addicts,
could be related to altered immune regulation. It is well established that heroin
addicts have an abnormally high incidence of auto-antibodies, false positive syphilis
serology, and hyperglobulinemia [19,20]; in addition, T cell function has been shown
to be impaired [21]. We have studied suppressor T cell function in heroin addicts and
have shown a defect when assessed by conconavalin A blast formation [22]. It may
then be proposed that, during active heroin use, effector T cell function is impaired
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(as shown by Brown et al. [21]), resulting in incomplete clearance of virus antigen
from the liver. A suppressor T cell defect allows for inappropriately high levels of
immunoglobulin and auto-antibody production. With withdrawal of the heroin, the
suppressor T cell defect abates, allowingfor normal immunoregulation, with gradual
reduction in the levels ofimmunoglobulin and auto-antibodies, as has been observed
when heroin addicts stop their drug abuse [23]. It is conceivable that the abnormali-
ties in immunefunction described in heroin addicts are unrelated to the persistence of
the hepatitis and that this persistence is merely a result of continuous, low-dose
infection by HBV. However, there is mounting evidence that the nature of the
immune response is all-important in the pathogenesis of the liver injury associated
with HBV infection [24,25], especially since the HBV appears not to be a cytopathic
virus in its own right [26,27].
It is thus apparent that the nature of the hepatitis in former drug addicts is a
complex one; the lesion is chronic, persisting for years after discontinuance ofheroin,
and appears to be related to HBV infection. There appears to be a similarity between
the immunological behavior, in terms of hepatitis serology, between hemophiliacs
and former drug addicts, a similarity which was not previously mentioned. It is
possible that study and comparison of the immune response in these two groups,
dissimilar as they may be in this respect, will result in better understanding of the
nature and mechanisms of chronic (unresolved) hepatitis, type B.
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